Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BF.38.3NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-4914.61China
BF.38.3NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BF.38.3NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BF.38.3NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BF.38.3ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BF.7.19.1ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
BF.7.19.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BF.7.19.1NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BF.7.19.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-4914.61China
BF.7.19.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BF.7.19.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BF.7.19.1NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BF.7.19.1ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BQ.1.1.43ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
BQ.1.1.43ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BQ.1.1.43NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BQ.1.1.43NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-4625.82China
BQ.1.1.43NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-21956.6US
BQ.1.1.43NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BQ.1.1.43NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BQ.1.1.43ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BA.5.2.12ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
BA.5.2.12ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.5.2.12NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.5.2.12NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.5.2.12NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.5.2.12NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BA.5.2.12NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BA.5.2.12ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BF.7.23ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
BF.7.23ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BF.7.23NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BF.7.23NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-4914.61China
BF.7.23NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BF.7.23NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BF.7.23NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BF.7.23ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.1.214ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
B.1.1.214ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.1.214NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
B.1.1.214NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-19013.6China
B.1.1.214NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.1.214NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.1.214NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.1.214ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.1.284ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
B.1.1.284ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.1.284NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
B.1.1.284NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.1.284NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used